{"doi":"10.1016/j.breast.2025.104437","title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer","abstract":null,"journal":"The Breast","year":2025,"id":611184,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":56758,"name":"Sara M. Tolaney","orcid":"0000-0002-5940-8671","position":1,"is_corresponding":false},{"id":605539,"name":"Denise A. Yardley","orcid":"0000-0002-8664-3458","position":2,"is_corresponding":false},{"id":1572580,"name":"Lowell Hart","orcid":null,"position":3,"is_corresponding":false},{"id":90747,"name":"Pedram Razavi","orcid":"0000-0003-4236-0576","position":4,"is_corresponding":false},{"id":33594,"name":"Peter A. Fasching","orcid":"0000-0003-4885-8471","position":5,"is_corresponding":false},{"id":683806,"name":"Wolfgang Janni","orcid":"0000-0001-5911-2400","position":6,"is_corresponding":false},{"id":1572581,"name":"Lee Schwartzberg","orcid":null,"position":7,"is_corresponding":false},{"id":1458605,"name":"Julia Kim","orcid":"0000-0002-3073-3331","position":8,"is_corresponding":false},{"id":1572582,"name":"Murat Akdere","orcid":null,"position":9,"is_corresponding":false},{"id":885979,"name":"Courtney McDermott","orcid":"0000-0001-6294-868X","position":10,"is_corresponding":false},{"id":1419182,"name":"Aamir Khakwani","orcid":"0000-0001-9257-1836","position":11,"is_corresponding":false},{"id":1572583,"name":"Purnima Pathak","orcid":null,"position":12,"is_corresponding":false},{"id":1187770,"name":"Stephanie L. Graff","orcid":"0000-0003-1928-1722","position":13,"is_corresponding":false},{"id":1541997,"name":"Joyce O'Shaughnessy","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer","abstract":"BACKGROUND: Despite adjuvant endocrine therapy (ET), recurrence is still a concern for patients with HR+/HER2- early breast cancer (EBC). We assessed recurrence risk in real-world patients with stage II/III HR+/HER2- EBC treated with adjuvant ET. METHODS: A retrospective analysis was conducted using the ConcertAI Patient360 database (January 1995 to April 2021) of patients with stage II/III HR+/HER2- EBC ≥18 years who underwent surgery and received adjuvant ET. Risk of recurrence was assessed using invasive disease-free survival (iDFS) with adapted STEEP criteria. An ET subanalysis evaluated iDFS, distant disease-free survival, and overall survival in patients receiving adjuvant non-steroidal aromatase inhibitors (NSAI) vs tamoxifen. RESULTS: In the full analysis cohort (N = 3133), the risk of an iDFS event was 26.1 % at 5 years, rising to 45.0 % at 10 years. Among patients with stage II disease, the risk of an iDFS event at 5 and 10 years was 22.7 % and 40.5 %, respectively; stage III 5- and 10-year risk was 40.4 % and 62.9 %. Patients with node-negative disease had 5- and 10-year risks of 22.1 % and 36.9 %, respectively; node-positive 5- and 10-year risk was 28.9 % and 49.4 %. ET subanalysis showed improved iDFS with NSAI ± ovarian function suppression vs tamoxifen ± ovarian function suppression (HR, 0.83; 95 % CI, 0.69-0.98; p = 0.031); this trend was observed regardless of menopausal status. CONCLUSIONS: This real-world study highlights the considerable risk of recurrence with adjuvant ET in patients with stage II or III HR+/HER2- EBC (including node-negative disease) and confirms the need for improved treatment options.","is_dataset_classified":null,"base_score":2.3978952727983707,"endowment":2.3978952727983707,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"40157276","pmcid":"PMC11995083","openalex_id":"https://openalex.org/W4408224923","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30 CA008748","title":null},{"funder_name":"Novartis Pharmaceuticals Corporation","grant_id":"","title":null}],"total_grants":2,"fwci":4.5613,"citation_percentile":0.95274353,"influential_citations":0,"citation_trend":[{"year":2025,"count":3},{"year":2026,"count":7}],"oa_status":"gold","license":"cc-by-nc-nd","oa_locations":[{"url":"https://www.thebreastonline.com/article/S0960-9776(25)00454-0/pdf","host_type":"journal"},{"url":"https://www.thebreastonline.com/article/S0960-9776(25)00454-0/pdf","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0960977625004540?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0960977625004540?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.breast.2025.104437","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/40157276","host_type":"repository"},{"url":"https://doaj.org/article/6eb01322546246aaa9d1486a4139d6d7","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11995083","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC11995083","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC11995083?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Breast Cancer Treatment Studies","Advanced Breast Cancer Therapies","Estrogen and related hormone effects"],"mesh_terms":["Adult","Aged","Breast Neoplasms","Female","Humans","Middle Aged","Neoplasm Recurrence, Local","Neoplasm Staging","Receptors, Estrogen","Retrospective Studies","Tamoxifen","Treatment Outcome","Chemotherapy, Adjuvant","Risk Assessment","Disease-Free Survival","Receptor, ErbB-2","Erb-b2 Receptor Tyrosine Kinases","Antineoplastic Agents, Hormonal","Aromatase Inhibitors"],"keywords":["Medicine","Stage (stratigraphy)","Oncology","Breast cancer","Adjuvant therapy","Adjuvant","Internal medicine","Endocrine system","Cancer","Gynecology","Hormone","Real World","Risk Of Recurrence","Hr+/her2-early Breast Cancer"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-01T16:28:38.715596Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}